Navigation Links
Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea

ent compliance. Since it is commonly known that an inverse relationship exists between compliance and dosing frequency, this finding holds significant promise for successful treatment of the papulopustular form of rosacea targeted for treatment by anti- inflammatory dose doxycycline.

The study concludes that "anti-inflammatory dose doxycycline is the only tetracycline agent proven to be effective for the treatment of rosacea in pivotal phase III clinical trials and exhibits a pharmacokinetic profile that separates the anti-inflammatory effects from antibiotic activities."

"The advent of this systemic treatment for rosacea portends a greater population of patients who experience satisfaction from the regimen recommended by their physician because the therapy is easy to comply with and avoids the consequences of antibiotic exposure for a disease where it has not been shown that an antibiotic effect is needed," said Dr. Del Rosso.

About CollaGenex

CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company currently focused on developing and marketing proprietary, innovative medical therapies to the dermatology market. In July 2006, CollaGenex launched Oracea(R), the first FDA-approved systemic product for the treatment of rosacea. CollaGenex's professional dermatology sales force also markets Pandel(R), a prescription topical corticosteroid licensed from Altana, Inc., Alcortin(R) (1% iodoquinol and 2% hydrocortisone), a prescription topical antifungal steroid combination, and Novacort(R) (2% hydrocortisone acetate and 1% pramoxine HCl), a prescription topical steroid and anesthetic. Alcortin and Novacort are marketed by the Company under a Promotion and Cooperation agreement with Primus Pharmaceuticals, Inc. CollaGenex is conducting a 400-patient, Phase II dose-finding study to evaluate its second dermatology candidate, incyclinide, for the treatment of acne. CollaGenex is also conducting Phase I clinical trials to evaluate COL-1
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Aspreva and Roche Announce Preliminary Results for Phase III Study Evaluating CellCept in Lupus Nephritis
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
5. New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At Annual Digestive Disease Week Meeting
6. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
7. King Pharmaceuticals Announces Plan to Report Positive Data from Phase III Clinical Trial Evaluating the Combination of Altace with Hydrochlorothiazide
8. Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for Psychotic Major Depression Misses Primary Endpoint
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Post Your Comments:
(Date:11/21/2014)... , Nov. 21, 2014 ... the European Medicines Agency (EMA) has granted ... company,s lead product candidate, for the treatment ... a rare, severely disabling genetic disease characterized ... swelling (flare-ups) and new abnormal bone formation. ...
(Date:11/21/2014)... LITTLE FALLS, N.J. , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL ... Andrew A. Krakauer , Chief Executive Officer, will be presenting ... at The New York Palace Hotel in New ... December 2, 2014 at 2:00 PM ET. In addition, Mr. ... will be available for separate one-on-one meetings during the day. ...
(Date:11/21/2014)... November 2014 Michael DeMarco (42) ... des 14. Februar 2014 zugetragen hat. Seine Tochter Aly ... Video - http://youtu.be/5cVoMCe0uiE ... mein morgendliches Training zu machen", erzählt Michael DeMarco ... Zeit begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3
... Inc. (Nasdaq: OMCL ) a leading provider of ... present at the UBS 21st Annual Global Healthcare Services Conference ... Omnicell Speakers: Rob Seim, vice president & CFO ... Tuesday, February 8, 2011Time: 11:00 a.m. ESTLocation: Grand ...
... 2011 Carrot Medical, a leading designer of integrated ... During the year, Carrot Medical achieved significant growth in ... private financing. Carrot Medical, recognized as a ... Technology solution that integrates medical images and other visual ...
Cached Medicine Technology:Omnicell to Present at the UBS 21st Annual Global Healthcare Services Conference 2Carrot Medical Reports 2010 Growth in Sales and Financing, Optimism for 2011 2
(Date:11/21/2014)... Porcelain veneer dentist, Dr. ... in preparation for the coming holiday season. Veneers, ultra-thin ... look completely natural, and can be used to permanently ... valued for their ability to strengthen teeth. Veneers are ... on one or several teeth to rejuvenate appearance. Check ...
(Date:11/21/2014)... Nov. 20, 2014 (HealthDay News) -- Seeking to make ... U.S. Food and Drug Administration on Thursday approved a ... Hydrocodone -- best known by the brand name ... been tied to a surge in dangerous addictions across ... approved Hysingla ER (hydrocodone bitartrate) is an extended-release tablet ...
(Date:11/21/2014)... 2014 (HealthDay News) -- Certain genes might prevent regular ... a fifth of people with type 2 diabetes, a ... pondered by doctors working with diabetic patients, one expert ... the impression that exercise helps decrease insulin resistance in ... director of the Center for Weight Management at North ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 Richard ... Solutions , will present advanced benefits administration strategies ... Annual Houston HR Leadership Summit. This Game Changer ... Resources industry to present cutting-edge solutions and best ... will explain how real-time data exchange between health ...
(Date:11/21/2014)... WOBURN, Mass. (PRWEB) November 21, 2014 ... two free workshops titled “Massachusetts Insurance Funding for Autism ... disorder (ASD) navigate their way through the insurance coverage ... covered under Massachusetts law and the most effective ways ... on Thursday, Dec. 4 from 6-8:00 p.m. at 331 ...
Breaking Medicine News(10 mins):Health News:Los Angeles Porcelain Veneers Dentist, Dr. Kevin Sands, Now Creates Picture-Perfect Smiles for Patients for the Holiday Season 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 2Health News:FDA Approves 'Abuse-Resistant' Narcotic Painkiller 3Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 2Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 3Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 2Health News:Empyrean Benefit Solutions CEO Sharing Latest Benefits Administration Strategies with Houston HR Leaders 3Health News:Center for Autism and Related Disorders to Host Massachusetts Autism Insurance Workshops for Parents 2
... Associates will host a community health fair in the Shoh-Sohail ... will include free health screenings for the local community, will ... VHA Building on the Mandalay Canal, 220 Las Colinas Blvd, ... will be hosted in an effort to inform, educate and ...
... the availability of Trade Alerts on stocks making news today. ... free by visiting: http://www.BeaconEquity.com/m Today,s Trade Alerts include: ... (NYSE: ABT ), Eli Lilly & Co. (NYSE: ... ), Novartis AG (NYSE: NVS ) and GlaxoSmithKline ...
... Feb. 18 SpectraScience, Inc. (OTC Bulletin Board: ... it will place its LUMA(R) Cervical Imaging System ... located in Edina, Minnesota.Dr. James B. Presthus, co-founder ... of the LUMA System represents our continued dedication ...
... affairs departments in deploying comprehensive investigator-initiated research grant management program ... ... 18, 2009 -- Clinipace, a growing clinical research solutions company, ... firms to deploy its TEMPO™ for Grant Management ...
... is warranted, experts say , , WEDNESDAY, Feb. 18 (HealthDay News) ... human fetal stem cell therapy has been reported in Moscow, ... to the growths. , The tumors appeared along ... after he began receiving the neural fetal stem cell treatment ...
... Feb. 18 Inverness Medical Innovations, Inc. (NYSE: ... charge of their health at home through the merger of ... for the quarter ended December 31, 2008.In the fourth quarter ... compared to net revenue of $288.0 million in the fourth ...
Cached Medicine News:Health News:Las Colinas FREE Community Health Fair Benefiting the Shoh-Sohail Family of Irving 2Health News:Beacon Equity Issues Technical Trade Alerts on Drug Manufacturers: JNJ, ABT, LLY, PFE, NVS, GSK 2Health News:LUMA Cervical Imaging System Installed in Edina at Minnesota Gynecology 2Health News:LUMA Cervical Imaging System Installed in Edina at Minnesota Gynecology 3Health News:Two Pharmaceutical Firms Select Clinipace to Deploy New Grant Management Solution 2Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 2Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 3Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 4Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 5Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 6Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 7Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 8Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 9Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 10Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 11Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 12Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 13Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 14Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 15Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 16Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 17Health News:Inverness Medical Innovations Announces Fourth Quarter 2008 Results 18
BD Beaver Phaco slit blade, 3.2 mm, angled 45, bevel up. matte finish offers a precise incision which minimizes leakage during phaco procedures. Precise incision minimizes leakage during phaco proced...
BD Beaver DeBakey blade, 5 mm cutting width, sterile....
... testing of large oculomotor imbalances ... all standard trial frames. Offer ... thin optical quality acrylic and ... a display box. Available as ...
... only powered 6-inch dermatome on the market. ... adult hands or a small child's face ... to run more efficiently, thus the motor ... temperature is much cooler. The Electro-Dermatome is ...
Medicine Products: